Ellie Leick

Articles

ELAINE Trial Explores Lasofoxifene in ESR1+ Breast Cancer

December 18th 2019

Matthew P. Goetz, MD, discusses the current treatment landscape for patients with estrogen receptor-positive, HER2-negative breast cancer who harbor ESR1 mutations, and provided an overview of the ELAINE trial.

More Research Must Focus on Later-Line Therapies in Ovarian Cancer

December 16th 2019

Casey M. Cosgrove, MD, discusses later-line treatments in ovarian cancer and ongoing research.

Addressing Belantamab Mafodotin-Related Corneal Events in Myeloma is Key to Continuing Treatment

December 6th 2019

Rakesh Popat, MD, discusses the DREAMM-1 trial and how to manage the corneal adverse events that result from belantamab mafodotin treatment in patients with relapsed/refractory myeloma.

Prostate Cancer Treatment Options Expand With ADT Combinations

December 4th 2019

David F. Penson, MD, MPH, MMHC, discusses the current armamentarium and ongoing research in prostate cancer.

CAR-T Progress Continues in Non-Hodgkin Lymphoma, But Guidelines Need Updating

December 3rd 2019

Miguel-Angel Perales, MD, discusses the evolving role of CAR T-cell therapy in diffuse large B-cell lymphoma and follicular lymphoma.

Expert Shares Insight on Recent Prostate Cancer Developments

November 27th 2019

Sam S. Chang, MD, discusses the utility of genetic testing in prostate cancer and pivotal research efforts.

Osimertinib Now Standard in Frontline EGFR+ NSCLC, But Potential for Progress Remains

November 27th 2019

Mary J. Fidler, MD, discusses how recent research has impacted the EGFR-mutant non–small cell lung cancer landscape.

Therapeutics Beyond JAK Inhibitors Needed in Polycythemia Vera and Myelofibrosis

November 27th 2019

Raajit K. Rampal, MD, PhD, discusses current available treatments for patients with polycythemia vera and myelofibrosis, as well as the unmet needs in this area of research.

Intriguing BCMA-Targeted Therapies Move Through Myeloma Pipeline

November 27th 2019

Investigators are exploring various treatment modalities in the multiple myeloma pipeline, many of them using BCMA as a target because of its high expression on myeloma cells.

Myriad Modalities Advance Multiple Myeloma Paradigm

November 27th 2019

Nina Shah, MD, discusses how CAR T-cell therapy, bispecific T-cell engagers, and antibody-drug conjugates are being used to treat patients with multiple myeloma.

Sequencing Challenges Emerge in Myeloma After Recent Approvals

November 26th 2019

Sham Mailankody, MBBS, discusses ongoing research and recent advances in relapsed/refractory multiple myeloma.

Expert Shares Insight on Evolution of Ovarian Cancer Therapeutics

November 21st 2019

Larry J. Copeland, MD, discusses how therapy for patients with ovarian cancer has evolved in recent years.

O'Malley Highlights Pivotal Trials in Ovarian Cancer

November 19th 2019

David O’Malley, MD, discusses clinical trials in ovarian cancer and others under investigation.

Up Front NGS Among Top Advances in Lung Cancer

November 19th 2019

Azadeh Namakydoust, MD, discusses recent advancements in lung cancer and what the future holds.

Genetic Testing Is Suggested First Step Upon Ovarian Cancer Diagnosis

November 18th 2019

Leigha Senter, MS, LGC, discusses the current state of genetic testing for patients with ovarian cancer.

Emergence of Biosimilars Poised to Alleviate Financial Toxicity in Oncology

November 16th 2019

Bradley G. Somer, MD, discusses the emergence of biosimilars in oncology

Pivotal Data in HER2+ Breast Cancer Transform Paradigm

November 13th 2019

Erika P. Hamilton, MD, discussed several studies in the HER2-positive breast cancer space and the sequencing challenges that have emerged.

CDK4/6 Inhibitors Show Unmatched OS Benefit in Metastatic HR+ Breast Cancer

November 12th 2019

Komal Jhaveri, MD, FACP, discusses updates in research for metastatic HR-positive, HER2-negative breast cancer.

Osimertinib Positioned as Preferred Frontline Treatment for EGFR-Mutant NSCLC

November 12th 2019

Zofia Piotrowska, MD, MHS, discusses the role of osimertinib in treating patients with EGFR-mutant non–small cell lung cancer and how it compares with other therapeutic options in that space.

Levy Lends Insight on Evolving Treatment Strategies in Lung Cancer

November 9th 2019

Benjamin P. Levy, MD, discusses therapeutic strategies for patients with oncogenic-driven and nondriver non–small cell lung cancer.